{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:43Z","timestamp":1787759323191,"version":"build-2784847793"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373965"],"award-info":[{"award-number":["82373965"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404769"],"award-info":[{"award-number":["82404769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024JJ5465"],"award-info":[{"award-number":["2024JJ5465"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Central Universities of Central South University","award":["2022ZZTS0850"],"award-info":[{"award-number":["2022ZZTS0850"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tigecycline is increasingly used off-label for hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB). While the standard-dose regimen (100\u2005mg loading dose followed by 50\u2005mg q12h) yields suboptimal outcomes, a high-dose regimen (200\u2005mg loading dose followed by 100\u2005mg q12h) has been proposed to improve efficacy, but its clinical benefits remain controversial. This study aimed to compare microbiological responses of standard- and high-dose tigecycline regimens under simulated lung exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two clinical CRAB isolates (CRAB21824 and CRAB21849) were characterized by tigecycline susceptibility testing and carbapenemase phenotypic\/genotypic analysis. A hollow-fibre infection model (HFIM) along with semi-mechanistic PK\/PD modelling was employed to simulate tigecycline pharmacokinetics in epithelial lining fluid of pneumonia patients and assess the antibacterial activity and resistance development under both dosing regimens. Tigecycline resistance mechanisms were investigated using whole-genome resequencing and molecular docking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tigecycline MICs were 1 and 0.25\u2005mg\/L for CRAB21824 and CRAB21849, respectively. Both strains carried blaOXA-66 and blaOXA-23, encoding Class D carbapenemase, but lacked Class A and B carbapenemases. HFIM-driven semi-mechanistic PK\/PD modelling revealed strain- and dose-dependent antibacterial activity of tigecycline. The high-dose regimen exhibited prolonged antimicrobial effects compared to standard dosing. However, it ultimately led to bacterial regrowth for CRAB21849, despite achieving the pharmacodynamic target of AUC0-24h\/MIC &amp;gt;4.5. A missense mutation in adeB (c.218T\u200a&amp;gt;\u200aG, p.Val73Gly) enhancing tigecycline efflux was identified as the resistance mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While high-dose tigecycline enhanced antibacterial efficacy, its failure to prevent efflux-mediated resistance in specific strains highlights the inherent limitations of dose escalation for CRAB pneumonia treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf477","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:10:23Z","timestamp":1765545023000},"source":"Crossref","is-referenced-by-count":1,"title":["Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant\n                    <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7225-4009","authenticated-orcid":false,"given":"Xiaonan","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University , Changsha 410013 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Certara (Shanghai) Pharmaceutical Consulting Co., Ltd , Shanghai 200021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-2810","authenticated-orcid":false,"given":"Feiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University , Changsha 410013 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeneng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University , Changsha 410013 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6719-9788","authenticated-orcid":false,"given":"Hanxi","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Science, Central South University , Changsha 410000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-2676","authenticated-orcid":false,"given":"Feifan","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University , Changsha 410013 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4007-7071","authenticated-orcid":false,"given":"Sanwang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University , Changsha 410011 ,","place":["China"]},{"name":"Institute of Clinical Pharmacy, Central South University , Changsha 410011 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902094542200_dkaf477-B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026011902094542200_dkaf477-B2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011902094542200_dkaf477-B3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026011902094542200_dkaf477-B4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1128\/AAC.01624-13","article-title":"In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii","volume":"58","author":"Hagihara","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1089\/mdr.2012.0010","article-title":"Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp","volume":"18","author":"Moon","year":"2012","journal-title":"Microb Drug Resist"},{"key":"2026011902094542200_dkaf477-B6","author":"FDA Drug Safety Communication"},{"key":"2026011902094542200_dkaf477-B7","doi-asserted-by":"publisher","first-page":"e00345-17","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026011902094542200_dkaf477-B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijantimicag.2009.01.015","article-title":"Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint","volume":"34","author":"Burkhardt","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902094542200_dkaf477-B10","doi-asserted-by":"publisher","first-page":"e0154123","DOI":"10.1128\/aac.01541-23","article-title":"Simulated drug disposition in critically ill patients to evaluate effective PK\/PD targets for combating Pseudomonas aeruginosa resistance to meropenem","volume":"68","author":"Zhang","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B11","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1093\/jac\/dkab160","article-title":"Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting","volume":"76","author":"Sadouki","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026011902094542200_dkaf477-B12","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B13","doi-asserted-by":"publisher","first-page":"904.e9","DOI":"10.1016\/j.cmi.2018.10.014","article-title":"A model-based analysis of pharmacokinetic-pharmacodynamic (PK\/PD) indices of avibactam against Pseudomonas aeruginosa","volume":"25","author":"Sy","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026011902094542200_dkaf477-B14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-informed drug development for antimicrobials: translational PK and PK\/PD modeling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026011902094542200_dkaf477-B15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/jac\/dkq210","article-title":"A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates","volume":"65","author":"Tsakris","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026011902094542200_dkaf477-B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF02712670","article-title":"A plant DNA minipreparation: version II","volume":"1","author":"Dellaporta","year":"1983","journal-title":"Plant Mol Biol Rep"},{"key":"2026011902094542200_dkaf477-B17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/cpt.1955","article-title":"Impact of disease on plasma and lung exposure of chloroquine, hydroxychloroquine and azithromycin: application of PBPK modeling","volume":"108","author":"Rowland Yeo","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026011902094542200_dkaf477-B18","doi-asserted-by":"publisher","first-page":"e0000425","DOI":"10.1128\/aac.00004-25","article-title":"Evaluating tigecycline dosing for hospital-acquired pneumonia patients: insights from physiologically-based pharmacokinetic modeling of lung exposure","volume":"69","author":"Zhang","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B19","doi-asserted-by":"publisher","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B20","doi-asserted-by":"publisher","first-page":"114558","DOI":"10.1016\/j.jpba.2021.114558","article-title":"An UPLC-PDA assay for simultaneous determination of seven antibiotics in human plasma","volume":"210","author":"Xie","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"2026011902094542200_dkaf477-B21","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/AAC.03639-14","article-title":"In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae","volume":"59","author":"Lim","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902094542200_dkaf477-B23","doi-asserted-by":"publisher","first-page":"e02642-16","DOI":"10.1128\/AAC.02642-16","article-title":"Substantial impact of altered pharmacokinetics in critically ill patients on the antibacterial effects of meropenem evaluated via the dynamic hollow-fiber infection model","volume":"61","author":"Bergen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B24","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1093\/jac\/dkac294","article-title":"Optimal ceftazidime\/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae","volume":"77","author":"Tam","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026011902094542200_dkaf477-B25"},{"key":"2026011902094542200_dkaf477-B26","doi-asserted-by":"publisher","first-page":"1417237","DOI":"10.3389\/fmicb.2024.1417237","article-title":"Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical Acinetobacter baumannii isolates in China","volume":"15","author":"Chen","year":"2024","journal-title":"Front Microbiol"},{"key":"2026011902094542200_dkaf477-B27","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1164\/ajrccm.156.6.9610117","article-title":"Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use","volume":"156","author":"Bonten","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026011902094542200_dkaf477-B28","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J Appl Physiol (1985)"},{"key":"2026011902094542200_dkaf477-B29","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1086\/509506","article-title":"Is panton-valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?","volume":"194","author":"Voyich","year":"2006","journal-title":"J Infect Dis"},{"key":"2026011902094542200_dkaf477-B30","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s10096-021-04262-x","article-title":"Revisiting the inoculum effect for Streptococcus pyogenes with a hollow fibre infection model","volume":"40","author":"Marum","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011902094542200_dkaf477-B31","doi-asserted-by":"publisher","first-page":"8395268","DOI":"10.1155\/2016\/8395268","article-title":"Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: a retrospective case study","volume":"2016","author":"Wu","year":"2016","journal-title":"BioMed Res Int"},{"key":"2026011902094542200_dkaf477-B32","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"2026011902094542200_dkaf477-B33","doi-asserted-by":"publisher","first-page":"e12467","DOI":"10.1097\/MD.0000000000012467","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026011902094542200_dkaf477-B34","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1128\/AAC.02556-12","article-title":"RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations","volume":"57","author":"Yoon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B35","doi-asserted-by":"publisher","first-page":"e0021722","DOI":"10.1128\/msystems.00217-22","article-title":"Differential binding of carbapenems with the AdeABC efflux pump and modulation of the expression of AdeB linked to novel mutations within two-component system AdeRS in carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Roy","year":"2022","journal-title":"mSystems"},{"key":"2026011902094542200_dkaf477-B36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1586\/eri.13.14","article-title":"Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management","volume":"11","author":"Pogue","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011902094542200_dkaf477-B37","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/antibiotics10080903","article-title":"Clinical outcomes and safety of meropenem-colistin versus meropenem-tigecycline in patients with carbapenem-resistant Acinetobacter baumannii pneumonia","volume":"10","author":"Park","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026011902094542200_dkaf477-B38","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1007\/s12010-021-03664-z","article-title":"In vitro activities of tigecycline in combination with amikacin or colistin against carbapenem-resistant Acinetobacter baumannii","volume":"193","author":"Wu","year":"2021","journal-title":"Appl Biochem Biotechnol"},{"key":"2026011902094542200_dkaf477-B39","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/mi15121517","article-title":"Hollow fiber microreactor combined with digital twin to optimize the antimicrobial evaluation process","volume":"15","author":"Noda","year":"2024","journal-title":"Micromachines (Basel)"},{"key":"2026011902094542200_dkaf477-B40","doi-asserted-by":"publisher","first-page":"e0031223","DOI":"10.1128\/aac.00312-23","article-title":"In vitro pharmacokinetics\/pharmacodynamics of the \u03b2-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex","volume":"68","author":"O'Donnell","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902094542200_dkaf477-B41","doi-asserted-by":"publisher","first-page":"448.e1","DOI":"10.1016\/j.cmi.2021.07.015","article-title":"Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics","volume":"28","author":"Ruth","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf477\/66444180\/dkaf477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf477\/66444180\/dkaf477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:09:55Z","timestamp":1768806595000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf477\/8429102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf477","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf477"}}